Chawla, N. S., Kuttschreuter, L., Sankhala, K. K., Benafif, S., Carter, L., Coupe, N., Evans, T. J., Humphries, T. G., Kao, S. C., Walter, H. S., Karabajakian, A., Grimaldi, A., Hoffmann, C., Low, G., Pierce, A., Champiat, S. (2025). INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2683